- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Crisil Ratings reaffirmed Lincoln Pharma's long-term bank facilities at "CRISIL A/Stable" and short-term facilities at "CRISIL A1." The "Stable" outlook reflects the group's strong market position, extensive promoter experience, and robust financial profile, including nil debt as of March 2025. Working capital intensity and regulatory risks remain partial offsets.